Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis

Published:2019-06 Issue:6 Volume:41 Page:1080-1089.e5
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Vanderpoel Julie,Tkacz Joseph,Brady Brenna L.,Ellis Lorie

Funder

This study was sponsored by Janssen Scientific Affairs, LLC

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference16 articles.

1. Understanding Rheumatoid Arthritis [Arthritis Foundation Website],2018

2. Rheumatoid Arthritis [Mayo Clinic Website],2018

3. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Rheumatol,2016

4. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment;Emery;Rheumatology (Oxford),2012

5. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study;Hyrich;Arthritis Rheum,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication;Advances in Therapy;2023-08-11

2. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study;Advances in Therapy;2021-11-09

3. Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis;Expert Opinion on Emerging Drugs;2021-07-03

4. Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review;Journal of Market Access & Health Policy;2021-01-01

5.

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity

;ClinicoEconomics and Outcomes Research;2020-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3